Access to the PDF text

Free Article !

Archives of cardiovascular diseases
Volume 102, n° S1
page 21 (mars 2009)
Doi : 10.1016/S1875-2136(09)72173-4
Themes et posters

B002 Proprotein convertase sublitisin kexin type 9 null mice are protected from postprandial triglyceridemia

C. Le May 1, S. Kourimate 1, C. Langhi 1, M. Chétiveaux 1, A. Jarry 2, C. Coméra 3, X. Collet 3, F. Kuipers 4, M. Krempf 1, B. Cariou 1, P. Costet 1
1 Inserm U915, Nantes, France 
2 EA Biometadys, Nantes, France 
3 Inserm U563, Toulouse, France 
4 University of Groningen, Groningen, The Netherlands 


Proprotein convertase subtilisin kexin type 9 (PCSK9) is a natural inhibitor of the low density lipoprotein receptor (LDLR) and its deficiency confers a high level of protection against cardiovascular disease. PCSK9 is well expressed in the liver and the intestine but its precise localization and its role in the digestive tract remain unknown.


The aim of this study is to determine PCSK9 distribution and localization in the intestine and examine in mice whether it acts upon postprandial lipemia.

Methods and Results

In mice, we show that PCSK9 mRNA is highly expressed all along the small intestine and colon. Confocal microscopy on human intestines showed that PCSK9 is localized mainly in the enterocyte. Similar to hepatocytes, PCSK9 was induced by statins in polarized Caco-2 cells. Upon olive oil gavage, and in spite of similar fasting triglyceridemia, PCSK9-/- mice have a dramatically decreased postprandial triglyceridemia compared with their wild type littermates (WT) (0.075g/L/h vs 0.2g/L/h, p<0.01). Lymph analysis revealed that intestinal TG output is not quantitatively modified by PCSK9 deletion. However, PCSK9-/- mice present a significant reduction of lymphatic apoB secretion compared to PCSK9+/+ mice. Modulating PCSK9 expression in polarized Caco-2 cells confirmed the relationship between PCSK9 and apoB secretion; PCSK9-/- mice consistently secrete larger TGrich lipoprotein than wild-type littermates. Finally, kinetic studies showed that PCSK9 deficient mice have an increased ability to clear chylomicrons compared to wild-type littermates.


Altogether, these data suggest that PCSK9 deficiency might protect against cardiovascular disease not only by affecting the LDLC but also by reducing postprandial triglyceridemia, an important risk factor.

The full text of this article is available in PDF format.
The full text of this article is available in PDF format.
Click here to see it.

Top of the page

© 2009  Elsevier Masson SAS. All Rights Reserved.
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Article Outline
You can move this window by clicking on the headline